Regenerative Medicine News & Intelligence Hub
The company has emerged from stealth mode with a new $21 million Series A tranche (bringing total funding to $42 million), appointed Ron Cohen, M.D. as CEO, and reported early Phase 1b/2a Parkinson’s neuron...
Weekly updates on regenerative medicine news, trials, and regulatory moves.
The company has emerged from stealth mode with a new $21 million Series A...
The lipid microbubble platform aims to enhance cell therapy manufacturing, adapted from its clinically...
The new open source gene editing services are ready to help iPSC developers create...
The new CellFiber Extruder aims to address manufacturing bottlenecks in cell therapy by enabling...
The new platforms aim to streamline large-scale production of iPSC-derived cell therapies for new...
The new graft material is designed for improved integration with patients' tissues, and it's...
The new clinic will offer stem cell therapies, AI-guided health management, and combine Eastern...
The company’s AI-powered CellForge™ platform aims to streamline and scale the production of engineered...
Nature Cell’s new facility will focus on stem cell therapeutics, research, and manufacturing, supported...
Indiana University’s new MAP-AD center will use stem-cell-derived brain models and AI to advance...
The company says its platform may fundamentally change how cartilage loss and degenerative joint disease is treated globally.
Based on their results in Korea/Japan, they received a Phase 3 fast track in the USA, and hope to show true cartilage regeneration. Potentially historic moment for the industry coming.
The new registry aims to address evidence gaps and track long-term outcomes for orthobiologic treatments.
Lineage will evaluate the new gene-edited iPSC line for immune compatibility and manufacturing potential before pursuing exclusive rights with Factor Bioscience.
Long-term follow-up suggests ProTrans may help preserve insulin production, with results varying by dose.
The collaboration will assess whether robotic automation can help scale up cell therapy manufacturing while maintaining GMP standards.
The partnership aims to streamline production and quality testing of gene-edited hematopoietic stem cell therapies for HIV and rare diseases.
With the right secured for stem cell potency, Longeveron is continuing its path forward with clinical trials for several mesenchymal stem cell indications.
The new open source gene editing services are ready to help iPSC developers create off-the-shelf allogeneic cell therapies at scale.
Polyphron will use Cellino's induced pluripotent stem cells in its "autonomous tissue foundry" to reproducibly manufacture cell and tissue therapies at scale.
The new CellFiber Extruder aims to address manufacturing bottlenecks in cell therapy by enabling scalable, GMP-compliant cell production.
The proposed legislation, if passed, will allow culture-expanded autologous mesenchymal stem cell therapies in the Cowboy State.
